Computed-Tomography Angiography-Based Carotid Plaque-RADS, Recurrent Vascular Events, and the Effect of Colchicine: An Imaging Substudy of the CONVINCE Randomized Trial
Authors:
- Louise MaesLMLouise Maes
- Anke WoutersAWAnke Wouters
- Jo P. PelusoJPJo P. Peluso
- Jelle DemeestereJDJelle Demeestere
- Philippe DesfontainesPDPhilippe Desfontaines
- Ronan CollinsRCRonan Collins
- Dominick J.H. McCabeDMDominick J.H. McCabe
- Simon CroninSCSimon Cronin
- David J. WilliamsDWDavid J. Williams
- Sylvie De RaedtSRSylvie De Raedt
- Francisco PurroyFrancisco Purroy
Open Access
- 22 October 2026
- journal article
- Published by Wolters Kluwer Health in Stroke
Abstract
BACKGROUND: The carotid Plaque Reporting and Data System (Plaque-RADS) provides a standardized framework for evaluating plaque morphology, but prospective validation remains limited. We investigated the association between computed tomography angiography-based Plaque-RADS categories and subsequent ischemic events in patients with noncardioembolic stroke/transient ischemic attack, from a completed clinical trial of colchicine. Second, we assessed whether the effect of colchicine differed by Plaque-RADS risk classification. METHODS: We conducted a posthoc observational cohort analysis of 517 participants in the CONVINCE trial (Colchicine for Prevention of Vascular Inflammation in Non-CardioEmbolic Stroke) from 13 European sites. Associations between Plaque-RADS and recurrent ipsilateral stroke, any stroke/transient ischemic attack, and major adverse cardiovascular events were assessed using multivariable Cox proportional hazards models. Plaque-RADS was analyzed as both dichotomized (P =0.01), any stroke/transient ischemic attack (adjusted hazard ratio, 3.94 [95% CI, 1.68–9.24]; P P =0.02) after adjustment for age, sex and cardiovascular risk factors. A significant interaction with colchicine treatment was observed for major adverse cardiovascular events ( P =0.047), with greater benefit among patients with Plaque-RADS scores ≥3 (hazard ratio, 0.35 [95% CI, 0.15–0.82]). CONCLUSIONS: In internal carotid arteries ipsilateral to the index ischemic stroke, computed tomography angiography-based carotid Plaque-RADS was associated with recurrent ischemic stroke and cardiovascular events. Importantly, treatment effects of colchicine varied across Plaque-RADS classification (<3 versus ≥3), suggesting that plaque vulnerability assessment may help refine patient selection for anti-inflammatory therapy beyond stenosis-based classification. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02898610.Keywords
This publication has 43 references indexed in Scilit:
- Carotid Artery Stenosis—An Impactful Bias in Ischemic Stroke ClassificationJAMA Cardiology, 2026
- Carotid Plaque-RADS Score Combined with Pericarotid Fat Density—An Incremental Prediction Model for Stroke RecurrenceAcademic Radiology, 2025
- Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias–A report from the European Society of Cardiology Cardiovascular Round TableJournal of Clinical Lipidology, 2024
- State-of-the-art CT and MR imaging and assessment of atherosclerotic carotid artery disease: the reporting—a consensus document by the European Society of Cardiovascular Radiology (ESCR)European Radiology, 2022
- Non-stenosing carotid artery plaques in embolic stroke of undetermined source: a retrospective analysisNeurological Sciences, 2022
- Carotid Plaque Characteristics Predict Recurrent Ischemic Stroke and TIAJACC: Cardiovascular Imaging, 2022
- Spectral photon-counting CT in cardiovascular imagingJournal of Cardiovascular Computed Tomography, 2021
- Vessel Wall–Imaging Biomarkers of Carotid Plaque Vulnerability in Stroke Prevention TrialsJACC: Cardiovascular Imaging, 2020
- Prediction of Stroke Risk by Detection of Hemorrhage in Carotid PlaquesJACC: Cardiovascular Imaging, 2020
- Carotid plaque inflammation on 18F‐fluorodeoxyglucose positron emission tomography predicts early stroke recurrenceAnnals of Neurology, 2012